A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor

Brief description of study

To evaluate the efficacy of pemigatinib in participants with locally advanced/metastatic or surgically unresectable solid tumor malignancy with an activating FGFR mutation or translocation.

Clinical Study Identifier: s19-01025
ClinicalTrials.gov Identifier: NCT03822117
Principal Investigator: Jeffrey G Schneider.
Other Investigator: Marissa Rybstein.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.